Skip to content
Screener

Regenxbio RGNX Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$6.4MMiss by $19.4M
EPS-$1.72Miss by $0.36
Revenue estimate$25.8M
EPS estimate-$1.36

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$15.9M
EPS estimate-$1.21

Financials

Q1 2026

Income statement

See full
Revenue$6.4M-92.8%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$432.52M+20.8%
Enterprise value$488.35M+58.6%
P/S4.9×+2.6×

Profitability

See full
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Segments

By product

See full
Zolgensma And Itvisma Royalties$5.1M-70.3%
Nippon Shinyaku Services$1.0M-43.0%
Other Service Revenue$292.0K+54.5%

FAQ

When did Regenxbio report Q1 2026 earnings?
Regenxbio (RGNX) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Regenxbio's Q1 2026 revenue and EPS?
Regenxbio reported revenue of $6.4M and eps of $-1.72 for Q1 2026.
Did Regenxbio beat estimates in Q1 2026?
Revenue missed the consensus estimate of $25.8M by $19.4M. EPS missed the consensus estimate of $-1.36 by $0.36.
How did Regenxbio's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 92.8% from $89.0M a year earlier.
Where can I find Regenxbio's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-222768) and the 10-Q periodic report (0001193125-26-222804) directly on SEC EDGAR. The filing index links above go to sec.gov.